Botulinum toxin type-A therapy in cluster headache: an open study.

Area of Science:

• Neurology
• Pain Medicine

Background:

• Cluster headache (CH) is a debilitating neurological disorder.
• Prophylactic treatment options for CH are limited, especially for patients unresponsive to standard therapies.

Purpose of the Study:

• To evaluate the efficacy and tolerability of botulinum toxin type-A (BTX-A) as an add-on prophylactic treatment for cluster headache.
• To assess BTX-A's effectiveness in both episodic and chronic CH subtypes.

Main Methods:

• An open, single-centre study involving twelve male patients with CH.
• Patients received a cumulative dose of 50 IU BTX-A via standardized pericranial muscle injections.
• Inclusion criteria required unresponsiveness to common prophylactic medications.

Main Results:

• One chronic CH patient achieved complete cessation of attacks.
• Two chronic CH patients experienced improvements in attack intensity and frequency.
• One chronic CH patient with continuous occipital headache showed significant improvement, though typical CH attacks were unaffected.
• No benefit was observed in patients with episodic CH.
• BTX-A demonstrated excellent tolerability.

Conclusions:

• BTX-A may offer a beneficial add-on prophylactic therapy for a subset of chronic cluster headache patients.
• Further research is warranted to identify predictors of response in chronic CH.
• BTX-A is not indicated for episodic cluster headache based on this study.